Roche's New GLP-1/GIP Drug CT-388 Shows 22.5% Weight Loss in Phase II — Phase III Starting Now

The GLP-1 market is about to get more crowded — and for patients, that's largely good news. Swiss pharmaceutical giant Roche announced positive Phase II results for CT-388, its investigational once-weekly injectable obesity drug, showing placebo-adjusted weight loss of up to 22.5% at 48 weeks in adults with obesity. Phase III trials are set to launch this quarter.

The results, published January 27, 2026, position Roche as a credible third force in a market currently dominated by Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound). While investors reacted with a modest 0.5% share gain — reflecting skepticism about a crowded market and a multi-year runway to launch — the clinical signal is meaningful for anyone tracking where obesity treatment is headed.

What Is CT-388?

CT-388 is a dual GLP-1/GIP receptor agonist — the same class of mechanism as tirzepatide (Zepbound/Mounjaro). It simultaneously activates both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, producing stronger appetite suppression and blood sugar regulation than single-target GLP-1 agonists like semaglutide alone.

Roche acquired CT-388 through its $2.7 billion purchase of U.S. biotech Carmot Therapeutics in 2023, a bet that dual-agonist approaches would define the next generation of metabolic therapies. The Phase II results now validate that strategy at the clinical level.

CT-388 is administered as a once-weekly subcutaneous injection — the same delivery format as Wegovy and Zepbound — making it directly comparable in patient experience to existing market leaders.

What the Phase II Results Actually Show

The trial tested five different doses of CT-388. At the highest dose, over 48 weeks:

• Per-protocol weight loss: 22.5% (placebo-adjusted, among participants who followed the full regimen)
• Intent-to-treat weight loss: 18.3% (placebo-adjusted, including patients who fell behind the treatment plan)
• Roche noted that longer treatment duration would likely yield additional weight loss

For context, tirzepatide (Zepbound) achieved approximately 20-22% weight loss at maximum doses in its SURMOUNT trials, and the landmark NEJM head-to-head trial published this month showed tirzepatide producing -20.2% versus -13.7% for semaglutide. CT-388's Phase II numbers land in the same range as tirzepatide's Phase III performance — a very strong signal for an investigational drug.

"The headline data released today puts CT-388 pretty much into the same efficacy ballpark as Zepbound," Jefferies analysts wrote in a research note following the announcement.

What Makes Roche Bullish Despite the Crowded Market

Roche's head of development, Manu Chakravarthy, has emphasized that the company believes CT-388 may offer a superior mode of action compared to existing GLP-1/GIP drugs — though this remains to be demonstrated in head-to-head trials.

There are several scenarios where CT-388 could carve out meaningful market share even against entrenched competitors:

Differentiated safety profile: If Phase III confirms a different side-effect signature — particularly around gastrointestinal tolerability, which drives a significant portion of discontinuations with current GLP-1s — CT-388 could appeal to patients who couldn't tolerate Wegovy or Zepbound.

Cardiovascular or organ-specific benefits: The GIP component of dual agonists has shown potential benefits beyond weight loss, including effects on bone metabolism, renal function, and potentially cardiovascular outcomes. If CT-388 proves superior in any of these domains, it could command premium positioning.

Combination potential: Roche is also pursuing amycretin and other novel obesity mechanisms. CT-388 could become a building block in combination therapies that push weight loss well beyond 25% — the next frontier in the field.

Market timing: By the time CT-388 completes Phase III and reaches approval — likely 2028-2029 at the earliest — the GLP-1 market will be substantially larger. A drug launching into a $100+ billion annual market with a differentiated profile doesn't need to beat Zepbound to be a commercial success.

Phase III: What to Watch

Roche announced that the Phase II results validated its design choices for two Phase III trials, which are set to begin in Q1 2026. These trials will:

• Enroll a much larger patient population (typically 2,000-5,000+ for obesity Phase III)
• Extend treatment duration beyond 48 weeks to establish long-term efficacy and safety
• Potentially include patients with diabetes and obesity-related comorbidities like cardiovascular disease
• Need to demonstrate not just weight loss but cardiovascular outcomes to achieve the full FDA label that semaglutide and tirzepatide now hold

Phase III trials typically take 2-4 years to complete. If everything goes well, a CT-388 FDA approval application would be expected no earlier than 2028.

What This Means for Patients Today

For patients currently evaluating GLP-1 treatment options, CT-388 is not yet a practical consideration — it won't be available for years. But the broader pipeline news matters for several reasons:

More competition = lower prices over time. Roche entering Phase III alongside other pipeline competitors (CagriSema, orforglipron, amycretin) signals that the obesity drug market will continue to face pricing pressure. The $1,000/month era for GLP-1s is ending — not just because of TrumpRx or Medicare deals, but because competitive dynamics will force it.

Better options are coming. The next-generation of obesity drugs — including dual and triple agonists, oral formulations, and combination therapies — may produce 25-30%+ average weight loss with better tolerability. Patients who are on the fence about current options may have compelling reasons to wait, or may find the pipeline results useful in conversations with their provider about what's ahead.

The science is maturing. Each Phase III readout teaches the field something new about durability, organ benefits, and safety profiles. The accumulating evidence base for GLP-1 class drugs is increasingly robust — a positive development for patient confidence in these therapies.

The Competitive Landscape in Early 2026

Here's a snapshot of where the major obesity drug programs stand:

• Wegovy (semaglutide, Novo Nordisk): Approved injectable + newly approved oral pill. Shortage resolved as of February 2026. Widely available.
• Zepbound/Mounjaro (tirzepatide, Lilly): Market-leading weight loss (~20%). $50/month Medicare deal. Phase III compounding ban 90-day clock running.
• Retatrutide (Lilly): Triple agonist in Phase III (TRIUMPH program), showing ~29% weight loss. Not yet approved.
• CT-388 (Roche): Phase III starting Q1 2026. ~22.5% in Phase II. Approval likely 2028-2029 at earliest.
• CagriSema (Novo Nordisk): Combination amylin + semaglutide showing ~20% weight loss. Phase III ongoing.
• Orforglipron (Lilly): Oral small-molecule GLP-1. Phase III complete; FDA submission pending. Could launch in 2026-2027.

When will Roche's CT-388 be available?

Based on Phase III timelines, the earliest realistic FDA approval for CT-388 would be 2028-2029. Patients should not expect to access this drug in the near term — current options (Wegovy, Zepbound, oral semaglutide) remain the practical choices today.

Is CT-388 better than Zepbound?

Phase II data suggests CT-388 achieves similar weight loss to tirzepatide (Zepbound) — roughly 18-22% at 48 weeks depending on how you measure it. Whether it will prove superior, equivalent, or different in important ways (safety, durability, organ benefits) depends on Phase III results. Head-to-head data against tirzepatide would be needed to definitively answer this question.

What should I do while waiting for next-generation obesity drugs?

The best obesity drugs that will ever exist are always the ones coming in 2-3 years. For patients who need treatment now, Wegovy and Zepbound are well-characterized, effective medications with strong long-term data. The pipeline should inform your expectations, not delay your care.